Phase I Study of Capmatinib in MET‐positive Solid Tumor Patients: Dose Escalation and Expansion of Selected Cohorts

Cancer Science - United States
doi 10.1111/cas.14254
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2011English

A Phase I Dose-Escalation Study of Intravenous Panobinostat in Patients With Lymphoma and Solid Tumors

Investigational New Drugs
OncologyPharmacology
2013English

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2016English

Phase I Dose‐escalation Study of Volasertib in Pediatric Patients With Acute Leukemia or Advanced Solid Tumors

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2019English

First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Phase 1 Dose-Escalation Study of Single-Agent Veliparib in Japanese Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2017English

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination With Bevacizumab in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2014English

P1.01-37 BPI-9016M, a Novel C-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results From a First-In-Human, Phase 1, Dose-Escalation Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy